UNSPSC 51322804: Acipimox

This classification denotes an anti-lipidemic agent with the molecular formula C6H6N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K9AY9IR2SD, chemically known as 2-pyrazinecarboxylic acid, 5-methyl-, 4-oxide but more generally known as acipimox, which bears U.S. NIH Compound Identifier 39880. European Medicines Agency schedules Acipimox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05237MIG.

UNSPSC 51322804 Acipimox is a Commodity code that encompasses individual pharmaceutical products supplied to state and local health agencies, public safety departments, and cooperative purchasing consortiums. The recent solicitations under this code reveal that state and local governments buy emergency-response medications, generic pharmaceuticals, and over-the-counter products through formal competitive bidding and cooperative procurement vehicles. Tampa Fire Rescue's acquisition of advanced life support medications (labetalol, epinephrine, adenosine, and diltiazem) typifies the scope — specific drugs in defined quantities, with strict expiration-date and shelf-life requirements, firm pricing inclusive of freight, and warranty provisions. The issuing bodies include city fire departments and emergency services (Tampa), state health and human services commissions (Texas HHS), and cooperative purchasing alliances spanning multiple states and municipalities (Minnesota Multistate Cooperative Purchasing Alliance). These buys are often sheltered for small local business enterprises, carry accessibility and safety-data-sheet compliance requirements, and run one to two years with optional renewals.

Recent activity concentrates in Florida, Texas, and Minnesota, with the latter operating a multi-state cooperative vehicle that extends across Oregon and other participating jurisdictions. Tampa's IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated value $40,000) sought four specific drug line items for Tampa Fire Rescue with a one-year term and three optional 30-day extensions. Minnesota's MMCAP RFP (Solicitation S1070000015802, due March 26, 2026) established multiple awards for generic pharmaceuticals and OTC products to be distributed across state and local facilities, with manufacturing compliance, wholesaler relationships, and competitive pricing as primary evaluation drivers. Texas HHS issued an exploratory RFI (HHS0017013, April 3, 2026) on direct-to-manufacturer prescription programs, signaling intent to reshape pharmacy procurement channels for state agencies and self-insured health plans. The code shows solid recent activity, though the Texas solicitation represents market research rather than a current buy opportunity.